Cargando…
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma
In the era of personalized treatment in multiple myeloma, high-risk patients must be accurately identified. The International Myeloma Working Group recommends using the Revised International Staging System (R-ISS) to pick out high-risk patients. The main purpose of our work was to explore the hetero...
Autores principales: | Schavgoulidze, Anaïs, Lauwers-Cances, Valérie, Perrot, Aurore, Cazaubiel, Titouan, Chretien, Marie-Lorraine, Moreau, Philippe, Facon, Thierry, Leleu, Xavier, Karlin, Lionel, Stoppa, Anne-Marie, Decaux, Olivier, Belhadj, Karim, Arnulf, Bertrand, Mohty, Mohamad, Mariette, Clara, Fohrer-Sonntag, Cécile, Lenain, Pascal, Marolleau, Jean-Pierre, Tiab, Mourad, Araujo, Carla, Orsini-Piocelle, Frédérique, Jaccard, Arnaud, Roussel, Murielle, Benboubker, Lotfi, Eveillard, Jean-Richard, Dib, Mamoun, Divoux, Marion, Attal, Michel, Avet-Loiseau, Hervé, Corre, Jill |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153521/ https://www.ncbi.nlm.nih.gov/pubmed/36172814 http://dx.doi.org/10.3324/haematol.2021.280566 |
Ejemplares similares
-
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
por: Talbot, Alexis, et al.
Publicado: (2023) -
Multiple Myeloma: Heterogeneous in Every Way
por: Schavgoulidze, Anaïs, et al.
Publicado: (2021) -
P872: DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE
por: Schavgoulidze, A., et al.
Publicado: (2022) -
Risk and Response-Adapted Treatment in Multiple Myeloma
por: Cazaubiel, Titouan, et al.
Publicado: (2020) -
All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
por: Touzeau, Cyrille, et al.
Publicado: (2022)